Epic Sciences unveils new liquid biopsy test to predict sensitivity to PARP inhibitors in prostate cancer trial

09:34 EDT 4 Apr 2019 | Compelo Medical Devices

The assay is being utilized as a selection device in BeiGene, Ltd.’s ongoing Phase 2 clinical trial with its investigational PARP inhibitor (pamiparib) in this patient population (NCT03712930).

More From BioPortfolio on "Epic Sciences unveils new liquid biopsy test to predict sensitivity to PARP inhibitors in prostate cancer trial"